US FDA warns 30 teleheath Cos. against illegal marketing of compounded GLP-1s

US FDA warns 30 teleheath Cos. against illegal marketing of compounded GLP-1s.

The FDA's warning to 30 telehealth companies about illegal marketing practices for compounded GLP-1 medications highlights growing scrutiny in the telehealth space. This may create increased regulatory risk for the companies involved, potentially impacting stock prices and investor sentiment. Investors should watch for any market reactions or further regulatory developments in this sector.